Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 13/20 | 0.52 |
| ▸ | MC4R | P32245 | 6/20 | 0.52 |
| ▸ | MC3R | P41968 | 6/20 | 0.52 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14541435 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL2669494 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL13068821 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL18433159 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4049536 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4049534 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL14627481 | 1.00 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL14627480 | 0.94 | MC5R (0.48) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4045701 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT | |
| SCHEMBL4045703 | 0.93 | MC5R (0.52) | MC5RMC4RMC3RMC1RNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203415-B1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2144891-B1 | 5-OXO-ISOXAZOLES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2766349-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI SA (FR) | 2016-06-01 | — | — | EP | disclosed |
| EP-1987042-B1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| EP-2061767-B1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| US-8841290-B2 | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2014-09-23 | — | — | US | disclosed |
| EP-2590931-B1 | (2-ARYLOXY-ACETYLAMINO)-PHENYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENT | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-1937675-B1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20070004743-A1 | Intranasal administration of mc4-r agonists | HEALTHPARTNERS RESEARCH FOUNDATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004743-A1 | Intranasal administration of mc4-r agonists | MC4R, MC5R, MC3R | MC5R 2/4885MC4R 1/4885MC3R 3/4885 |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | MC5R 944/4885MC4R 632/4885MC3R 1057/4885 |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | PAH, MCHR1, DHPS | MC5R 40/4885MC4R 51/4885MC3R 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.